Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to Evaluate Safety and Tolerability of Tazemetostat in Relapsed/Refractory Peripheral T-cell Lymphoma

NCT05983965 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT05983965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05983965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to Evaluate Safety and Tolerability of Tazemetostat in Relapsed/Refractory Peripheral T-cell Lymphoma
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 1
Overall status
Terminated
Start date
September 5, 2024
Completion date
March 6, 2026
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell lymphoma